MeSH tree: C15.604.515.569.480.150.585
People aged 80 and older with a common type of lymphoma can take a half-dose of chemotherapy and be cured or significantly extend their survivorship with fewer toxic side effects, a new study shows.
Dec 17, 2025
0
13
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, ...
Dec 8, 2025
0
12
Cancer isn't just about broken genes—it's about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services. That's what happens inside cells when the 3D structure of ...
Dec 6, 2025
0
83
By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD Anderson Cancer Center have identified seven distinct cellular microenvironments, providing a framework ...
Oct 22, 2025
0
23
A Northwestern Medicine study has uncovered new insights that may aid in understanding and potentially treating one of the most common and aggressive forms of non-Hodgkin lymphoma, according to findings published in Science ...
Sep 1, 2025
0
27
Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects the lymphatic system. It makes up around 30–40% of adult non-Hodgkin lymphoma cases worldwide. ...
Apr 22, 2025
0
12
An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, has made a major breakthrough in treating a common and challenging form ...
Jan 23, 2025
0
19
A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study by researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer ...
Dec 7, 2024
0
143
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity ...
Jul 24, 2024
0
34
A study led by researchers at Brighton and Sussex Medical School (BSMS) has unveiled an approach to predicting the effectiveness of treatments for patients with diffuse large B-cell lymphoma (DLBCL), a common form of blood ...
Jul 15, 2024
0
35
